Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Abstract:

BACKGROUND:To evaluate the immunological impact of the 23-valent pneumococcal polysaccharide vaccine (23vPPS) at 12 months, for children who have received zero to three infant doses of seven-valent pneumococcal conjugate vaccine (PCV), on responses to a subsequent exposure to a small dose of 23vPPS (mPPS). METHODS:Five hundred and fifty-two Fijian infants were stratified by ethnicity and randomized into eight groups to receive zero, one, two, or three PCV doses at 14 weeks, six and 14 weeks, or six, ten, and 14 weeks. Within each group, half received 23vPPS at 12 months and all received mPPS at 17 months. Sera were taken prior and one month post-mPPS. FINDINGS:By 17 months, geometric mean antibody concentrations (GMC) to all 23 serotypes in 23vPPS were significantly higher in children who had received 23vPPS at 12 months compared to those who had not. Post-mPPS, children who had not received the 12 month 23vPPS had a significantly higher GMC for all PCV serotypes compared with those who had (each p<0.02). For the non-PCV serotypes, children who had not received the 12 month 23vPPS had significantly higher GMC for six of 16 non-PCV serotypes (7F, 9N, 12F, 19A, 22F, 33F) than those who did (each p<0.02). After adjusting for the pre-mPPS level, exposure to 23vPPS was associated with a lower response to mPPS for all serotypes (each p<0.001). INTERPRETATION:Despite higher antibody concentrations at 17 months in children who had received 23vPPS at 12 months, the response to a re-challenge was poor for all 23 serotypes compared to children who had not received the 12 month 23vPPS.

journal_name

Vaccine

journal_title

Vaccine

authors

Russell FM,Carapetis JR,Balloch A,Licciardi PV,Jenney AW,Tikoduadua L,Waqatakirewa L,Pryor J,Nelson J,Byrnes GB,Cheung YB,Tang ML,Mulholland EK

doi

10.1016/j.vaccine.2010.02.087

subject

Has Abstract

pub_date

2010-04-26 00:00:00

pages

3341-9

issue

19

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(10)00279-3

journal_volume

28

pub_type

杂志文章,随机对照试验

相关文献

VACCINE文献大全
  • Expression of human antibodies in eukaryotic micro-algae.

    abstract::Protein based therapeutics have enjoyed great success over the past decade. Unfortunately, with this clinical success comes a heavy price tag, owing to the inherently high costs of capitalization and production using mammalian cell fermentation. To address this problem, we have begun developing a system for the expres...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2004.11.013

    authors: Mayfield SP,Franklin SE

    更新日期:2005-03-07 00:00:00

  • Lack of immune interference between inactivated polio vaccine and inactivated rotavirus vaccine co-administered by intramuscular injection in two animal species.

    abstract::A parenteral inactivated rotavirus vaccine (IRV) in development could address three problems with current live oral rotavirus vaccines (ORV): their lower efficacy in low and middle-income countries (LMICs), lingering concerns about their association with intussusception, and their requirement for a separate supply cha...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2018.12.043

    authors: Wang Y,Zade J,Moon SS,Weldon W,Pisal SS,Glass RI,Dhere RM,Jiang B

    更新日期:2019-01-29 00:00:00

  • Comparative analysis of immunization schedules using a novel adenovirus-based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.

    abstract::Development of active targeted immunotherapeutics is a rapid developing field in the arena of chronic infectious diseases. The question of repeated, closely spaced administration of immunotherapeutics to achieve a rapid impact on the replicating agent is an important one. We analyzed here, using a prototype adenovirus...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.03.089

    authors: Boukhebza H,Dubois C,Koerper V,Evlachev A,Schlesinger Y,Menguy T,Silvestre N,Riedl P,Inchauspé G,Martin P

    更新日期:2014-05-30 00:00:00

  • Influenza vaccination in paediatric nurses: cross-sectional study of coverage, refusal, and factors in acceptance.

    abstract:BACKGROUND:Influenza vaccination among health-care workers is poor, and the effectiveness of hospital vaccination programs remains unclear. Little is known about the effectiveness of intensive evidence-based vaccination programs in nursing staff. We determined whether the recommended vaccination rate could be achieved ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.03.033

    authors: Norton SP,Scheifele DW,Bettinger JA,West RM

    更新日期:2008-06-02 00:00:00

  • Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine.

    abstract::Enterovirus type 71 (EV71) and coxsackievirus A 16 (CA16) are recognized as the major pathogens responsible for human hand-foot-mouth disease. To develop a bivalent EV71-CA16 vaccine, rhesus macaques immunized with two doses of this vaccine via the intradermal route were challenged with EV71 or CA16, and their clinica...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.12.057

    authors: Fan S,Liao Y,Jiang G,Jiang L,Wang L,Xu X,Feng M,Yang E,Zhang Y,Cui W,Li Q

    更新日期:2020-02-18 00:00:00

  • No evidence of cross-reactivity of human antibodies to a 33-mer peptide of the alpha-gliadin component of gluten with Bordetella pertussis pertactin.

    abstract::A 33-mer peptide of the alpha-gliadin component of gluten was recently identified as primary initiator of the inflammatory response to gluten in coeliac disease (CD) patients. This proline-glutamine-rich peptide (PG-peptide) is highly homologous to internal sequence of pertactin, an immunogenic protein of Bordetella p...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.01.078

    authors: He Q,Viljanen MK,Hinkkanen AE,Arvilommi H,Mertsola J,Viander M

    更新日期:2005-05-09 00:00:00

  • Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves.

    abstract::Two modified live attenuated vaccines against the disease Rift Valley fever (RVF) have been tested for safety and efficacy in young calves. The RVF Smithburn vaccine produced in South Africa and used successfully to prevent and control the disease in endemic sub-Saharan countries was compared to the candidate vaccine ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2011.05.055

    authors: von Teichman B,Engelbrecht A,Zulu G,Dungu B,Pardini A,Bouloy M

    更新日期:2011-08-05 00:00:00

  • A passive cold storage device economic model to evaluate selected immunization location scenarios.

    abstract:BACKGROUND:The challenge of keeping vaccines cold at health posts given the unreliability of power sources in many low- and middle-income countries and the expense and maintenance requirements of solar refrigerators has motivated the development of passive cold storage devices (PCDs), containers that keep vaccines cold...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.08.079

    authors: Norman BA,Nourollahi S,Chen SI,Brown ST,Claypool EG,Connor DL,Schmitz MM,Rajgopal J,Wateska AR,Lee BY

    更新日期:2013-10-25 00:00:00

  • A qualitative study on knowledge, perceptions, and attitudes of mothers and health care providers toward pneumococcal conjugate vaccine in Bandung, West Java, Indonesia.

    abstract:UNLABELLED:Due to the high burden of pneumonia in Indonesia, the inclusion of pneumococcal conjugate vaccine (PCV) into Indonesia's National Immunization Program (NIP) is recommended by World Health Organization. Prior to the introduction of new vaccines, it is imperative to assess the perceptions of the public and med...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.01.007

    authors: Harjaningrum AT,Kartasasmita C,Orne-Gliemann J,Jutand MA,Goujon N,Koeck JL

    更新日期:2013-03-01 00:00:00

  • A randomized, phase 1/2 trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants.

    abstract:BACKGROUND:Neisseria meningitidis serogroup B (MnB) is a major cause of invasive meningococcal disease in infants. A conserved, surface-exposed lipoprotein, LP2086 (a factor H-binding protein [fHBP]), is a promising MnB vaccine target. A bivalent, recombinant vaccine targeting the fHBP (rLP2086) of MnB was developed. ...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2014.07.049

    authors: Martinon-Torres F,Gimenez-Sanchez F,Bernaola-Iturbe E,Diez-Domingo J,Jiang Q,Perez JL

    更新日期:2014-09-08 00:00:00

  • An improved Pythium insidiosum-vaccine formulation with enhanced immunotherapeutic properties in horses and dogs with pythiosis.

    abstract::The immunotherapeutic properties of a new Pythium insidiosum-vaccine formulation (PIV), was evaluated in 18 horses and 6 dogs with proven pythiosis from different enzootic areas in the United States. All injected horses but one responded with a weak (=29 mm, n=3), a mild (30-90 mm, n=7) or a strong (=100 mm, n=7) infl...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00225-1

    authors: Mendoza L,Mandy W,Glass R

    更新日期:2003-06-20 00:00:00

  • A humanized monoclonal antibody targeting Staphylococcus aureus.

    abstract::This current presentation describes the in vitro and in vivo characterization of Aurexis (tefibazumab), a humanized monoclonal antibody that exhibits a high affinity and specificity and for the Staphylococcus aureus MSCRAMM (Microbial Surface Components Recognizing Adhesive Matrix Molecules) protein ClfA. Aurexis inhi...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2004.08.015

    authors: Patti JM

    更新日期:2004-12-06 00:00:00

  • Tail scarification with Vaccinia virus Lister as a model for evaluation of smallpox vaccine potency in mice.

    abstract::Since smallpox eradication by the WHO during the 1980s, potency of new vaccines is compared to vaccines that were used during the eradication campaign. In this work we characterize the tail scarification technique in mice as a model for scarification in humans. Similar to humans, mice develop "clinical take" which is ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.09.023

    authors: Melamed S,Paran N,Katz L,Ben-Nathan D,Israely T,Schneider P,Levin R,Lustig S

    更新日期:2007-11-07 00:00:00

  • Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens.

    abstract::The development of potent adjuvants, conditioning innate and adaptative immunity, particularly CTL responses, has become currently a hot point in the rational design of vaccines for cancer immunotherapy. We have described a new approach, in which gangliosides are incorporated into vesicles from Neisseria meningitidis ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.111

    authors: Mesa C,de León J,Fernández LE

    更新日期:2006-03-24 00:00:00

  • Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity.

    abstract::We evaluated invasive pneumococcal disease (IPD), antimicrobial resistance and nasopharyngeal colonization before and after introduction of pneumococcal conjugate vaccine (PCV7) in Alaska Natives (AN), a population with high IPD rates. We obtained IPD rates from population-based surveillance. Colonization was determin...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.08.100

    authors: Hennessy TW,Singleton RJ,Bulkow LR,Bruden DL,Hurlburt DA,Parks D,Moore M,Parkinson AJ,Schuchat A,Butler JC

    更新日期:2005-12-01 00:00:00

  • Relation of activation-induced deaminase (AID) expression with antibody response to A(H1N1)pdm09 vaccination in HIV-1 infected patients.

    abstract::The relevance of CD4+T-cells, viral load and age in the immunological response to influenza infection and vaccination in HIV-1 infected individuals has previously been pointed out. Our study aimed at assessing, in the setting of 2009 A(H1N1)pdm09 influenza vaccination, whether quantification of activation-induced deam...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.03.002

    authors: Cagigi A,Pensieroso S,Ruffin N,Sammicheli S,Thorstensson R,Pan-Hammarström Q,Hejdeman B,Nilsson A,Chiodi F

    更新日期:2013-04-26 00:00:00

  • Evaluating the effectiveness of national measles elimination action in mainland China during 2004-2016: A multi-site interrupted time-series study.

    abstract:BACKGROUND:To block transmission of measles, the China Ministry of Health endorsed the "2006-2012 National Measles Elimination Action Plan (NMEAP)" on November 11, 2006, while no published studies used mathematical models to assess the impact of this action. Also, the problem of residuals autocorrelation due to auto-co...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2020.04.053

    authors: Xu L,Chen J,Zhan Z,Chen T,Liu W,Qian J,Ou C

    更新日期:2020-06-09 00:00:00

  • Evaluation of an intracellular-activated promoter for the generation of live Salmonella recombinant vaccines.

    abstract::Salmonella enterica serovar Typhimurium is a versatile host organism for the generation of recombinant live vaccines for mucosal immunization. We investigated the performance of an intracellular-activated promoter for expression of heterologous antigens by Salmonella carrier strains. We observed that intracellular exp...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2004.11.035

    authors: Husseiny MI,Hensel M

    更新日期:2005-04-08 00:00:00

  • Systems vaccinology: Enabling rational vaccine design with systems biological approaches.

    abstract::Vaccines have drastically reduced the mortality and morbidity of many diseases. However, vaccines have historically been developed empirically, and recent development of vaccines against current pandemics such as HIV and malaria has been met with difficulty. The advent of high-throughput technologies, coupled with sys...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.03.072

    authors: Hagan T,Nakaya HI,Subramaniam S,Pulendran B

    更新日期:2015-09-29 00:00:00

  • Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.

    abstract::Pregnant goats were employed to assess unmarked deletion mutant vaccine candidates BMDeltaasp24, BMDeltacydBA, and BMDeltavirB2, as the target host species naturally infected with Brucella melitensis. Goats were assessed for the degree of pathology associated with the vaccine strains as well as the protective immunity...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.04.005

    authors: Kahl-McDonagh MM,Elzer PH,Hagius SD,Walker JV,Perry QL,Seabury CM,den Hartigh AB,Tsolis RM,Adams LG,Davis DS,Ficht TA

    更新日期:2006-06-12 00:00:00

  • The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease.

    abstract::A small number of serotypes are responsible for most invasive pneumococcal disease in children worldwide. Serotypes 1 and 5 were among the first pneumococcal serotypes to be identified, reflecting their great prominence as causes of disease in the early part of the 20th century. In the antibiotic era, these serotypes ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2006.09.009

    authors: Hausdorff WP

    更新日期:2007-03-22 00:00:00

  • Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.

    abstract::In a phase I/II dose escalation study, varying volumes (0.1 ml, 0.5 ml, 1.0 ml and 2.0 ml) of 7-valent pneumococcal conjugate vaccine (PCV) (Prevnar or 0.5 ml of 23-valent pneumococcal polysaccharide vaccine (PPV) were administered to 220 adults 70 through 79 years of age previously vaccinated with 0.5 ml PPV at age 6...

    journal_title:Vaccine

    pub_type: 临床试验,杂志文章

    doi:10.1016/j.vaccine.2005.02.017

    authors: Jackson LA,Neuzil KM,Whitney CG,Starkovich P,Dunstan M,Yu O,Nelson JC,Feikin DR,Shay DK,Baggs J,Carste B,Nahm MH,Carlone G

    更新日期:2005-05-25 00:00:00

  • Peptide-binding assays and HLA II transgenic Abeta degrees mice are consistent and complementary tools for identifying HLA II-restricted peptides.

    abstract::The identification of MHC class II-restricted peptides has become a priority for the development of peptide-based prophylactic and therapeutic vaccines. The aim of this study was to assess the correlations between peptide-binding assays on purified HLA II molecules and immunization of human HLA II transgenic mice defi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2005.11.048

    authors: Depil S,Angyalosi G,Moralès O,Delacre M,Delhem N,François V,Georges B,Hammer J,Maillère B,Auriault C,Pancré V

    更新日期:2006-03-20 00:00:00

  • The feasibility of HIV vaccine efficacy trials among Russian injection drug users.

    abstract::IDU exposure remains a primary driver of the Russian HIV epidemic, and recent incidence data provide little evidence that this epidemic is slowing. While there are multiple important challenges that need to be further explored before starting vaccine trials, most importantly access to evidence-based drug treatment ser...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.07.028

    authors: Beyrer C,Baral S,Shaboltas A,Dukhovlinova E,Masharsky A,Verevochkin S,Latkin C,Heimer R,Hoffman I,Kozlov A

    更新日期:2007-10-10 00:00:00

  • High tetanus and diphtheria antitoxin concentrations in Finnish adults--time for new booster recommendations?

    abstract::The tetanus and diphtheria vaccination programme in Finland has been running for 50 years. After primary doses, tetanus boosters have been offered to men in military service and decennial boosters recommended for all through the adult life. For 30 years a diphtheria booster was only offered to men in the military serv...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2009.06.080

    authors: Olander RM,Auranen K,Härkänen T,Leino T

    更新日期:2009-08-27 00:00:00

  • Dosing regimen of the 23-valent pneumococcal vaccination: a systematic review.

    abstract:BACKGROUND:Currently, one lifetime booster of a 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for those at highest risk of invasive pneumococcal disease (IPD) 3-5 years after initial vaccination. Due to a lack of evidence on multiple revaccinations, recommendations on repeat revaccination do not ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2015.01.060

    authors: Caya CA,Boikos C,Desai S,Quach C

    更新日期:2015-03-10 00:00:00

  • Improved immunogenicity of a core-coated tetanus toxoid delivery system.

    abstract::A new microparticulate delivery system composed of a stabilizing gelatin/poloxamer microcore surrounded by a PLGA coat was designed to improve the stability of tetanus toxoid (TT) encapsulated in PLGA microspheres. Microcores were prepared by a spray-congealing technique and encapsulated within PLGA using an oil-in-oi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(99)00313-8

    authors: Tobío M,Schwendeman SP,Guo Y,McIver J,Langer R,Alonso MJ

    更新日期:1999-11-12 00:00:00

  • Safety and immunogenicity of an improved oral inactivated multivalent enterotoxigenic Escherichia coli (ETEC) vaccine administered alone and together with dmLT adjuvant in a double-blind, randomized, placebo-controlled Phase I study.

    abstract:BACKGROUND:We have developed a new oral vaccine against enterotoxigenic Escherichia coli (ETEC), which is the most common cause of bacterial diarrhea in children in developing countries and in travelers. METHODS:The vaccine was tested for safety and immunogenicity alone and together with double-mutant heat-labile toxi...

    journal_title:Vaccine

    pub_type: 杂志文章,随机对照试验

    doi:10.1016/j.vaccine.2014.10.069

    authors: Lundgren A,Bourgeois L,Carlin N,Clements J,Gustafsson B,Hartford M,Holmgren J,Petzold M,Walker R,Svennerholm AM

    更新日期:2014-12-12 00:00:00

  • Aluminum salts in vaccines--US perspective.

    abstract::Aluminum in the form of aluminum hydroxide, aluminum phosphate or alum has been commonly used as an adjuvant in many vaccines licensed by the US Food and Drug Administration. Chapter 21 of the US Code of Federal Regulations [610.15(a)] limits the amount of aluminum in biological products, including vaccines, to 0.85 m...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/s0264-410x(02)00166-4

    authors: Baylor NW,Egan W,Richman P

    更新日期:2002-05-31 00:00:00

  • Independent but not synergistic enhancement to the immunogenicity of DNA vaccine expressing HIV-1 gp120 glycoprotein by codon optimization and C3d fusion in a mouse model.

    abstract::The ability to elicit humoral and cell-mediated immune (CMI) responses from DNA immunization by combinational use of codon optimization and C3d component of complement was evaluated in this study. DNA vaccines that express either the wild type or the codon optimized gp120 gene coding for the envelope (Env) glycoprotei...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.09.054

    authors: Liu F,Mboudjeka I,Shen S,Chou TH,Wang S,Ross TM,Lu S

    更新日期:2004-04-16 00:00:00